Skip to content
Disclosery

RP Management, LLC

Follow

13F filer, CIK 1507673, New York, NY

RP Management, LLC reported $227,733,574 across 4 holdings for the quarter ended 2024-12-31, in a 13F-HR filed 2025-02-03.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001507673-25-000003

Period
2024-12-31
Reported value
$228M
Holdings
4
Top 10 weight
100%
New
0
Sold out
0

Holdings, Q4 2024

Share positions as resolved from 13F-HR 0001507673-25-000003, largest first. % of portfolio is the value over $227,733,574, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
BHVNBIOHAVEN LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: 2,936,507 shares; 2023Q4: 2,936,507 shares; 2024Q1: 2,936,507 shares; 2024Q2: 2,936,507 shares; 2024Q3: 2,936,507 shares; 2024Q4: 2,936,507 shares 2,936,507$147M64.43%0Timeline
CYTKCYTOKINETICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: not reported; 2024Q2: 980,392 shares; 2024Q3: 980,392 shares; 2024Q4: 980,392 shares 980,392$51.8M22.73%0Timeline
BCRXBIOCRYST PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: 3,846,154 shares; 2023Q4: 3,846,154 shares; 2024Q1: 3,846,154 shares; 2024Q2: 3,846,154 shares; 2024Q3: 3,846,154 shares; 2024Q4: 3,846,154 shares 3,846,154$29.2M12.84%0Timeline
VIRACTA THERAPEUTICS INCVIRACTA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: 3,700 shares; 2023Q4: 3,700 shares; 2024Q1: 3,700 shares; 2024Q2: 3,700 shares; 2024Q3: 3,700 shares; 2024Q4: 3,700 shares 3,700$851<0.01%0

How Q4 2024 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001507673-25-000003 base2025-02-03acceptance time not in the bulk data set